1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

  • January 2014
  • 64 pages
  • GlobalData
Report ID: 2070155

Summary

Table of Contents

Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] is Merck’s bivalent combination vaccine that offers protection against infections caused by Hib and all known subtypes of HBV. Comvax contains the antigenic components used in Merck’s PedvaxHIB and Recombivax HB vaccines. Upon receiving FDA approval for use in infants six weeks to 15 months of age in 1996, Comvax became the first combination vaccine in the US to protect its recipients against HBV infection. Currently, Comvax is only marketed in the US, as its EU market authorization, under the name Procomvax, was not renewed in 2009.

Scope

- Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Comvax including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Comvax for the US from 2012 to 2022.
- Sales information covered for the US

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Comvax performance
- Obtain sales forecast for Comvax from 2012-2022 in the US.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6995
  • Industry report
  • June 2017
  • by GBI Research

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation Summary Liver plays various vital roles within the body, including the removal of toxins from the blood, the production ...

Global Hepatitis Markers Testing Market 2021: Supplier Shares and Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures--Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices

  • $ 6250
  • Industry report
  • July 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...

Hepatitis A, B, C, D, E Diagnostics Market 2021: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and NAT Tests, Technology and Instrumentation Review

  • $ 6250
  • Industry report
  • June 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...


Download Unlimited Documents from Trusted Public Sources

Type 2 Diabetes Statistics in the US

  • August 2017
    13 pages
  • Type 2 Diabetes  

    Diabetes  

  • United States  

View report >

Smoking Statistics Industry in the UK and Europe

  • August 2017
    156 pages
  • Smoking Statist...  

    Mortality  

    Sexually Transm...  

  • Europe  

    United Kingdom  

View report >

Infectious Disease Statistics

  • August 2017
    188 pages
  • Infectious Dise...  

  • United States  

    Europe  

    Africa  

View report >

Related Market Segments :

Hepatitis
Vaccine

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.